{
  "docId": "019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "docSlug": "8c206fa848e149a61a796c5e8f53c9e1",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 37,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Clinical trial data presentation with statistical significance markers and MCID thresholds.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a7a3-7510-9ab9-5e74cd7e6c44/18",
  "deckHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "deckJsonHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44.json",
  "deckAnchorHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.15,
        "y": 0.77
      },
      "kind": "callout",
      "text": "Positive Trend in GMFM-E in Placebo-Controlled Study Suggests Potential Improvement in Mobility",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "807de16d-ce6a-4832-8f95-2b94b65d6b85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Mean Change from Baseline in 2MWT",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19607aa1-242b-470b-8e48-2bc7121cc19b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.06,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Mean Change from Baseline in GMFM-E",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80355c16-d197-4607-af95-0d9aa4e90d85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.55,
        "x": 0.23,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Enns G, et al. Poster presented at SIMD 2022 Annual Meeting; 1 MCID is minimal clinically important difference defined in Cerebral Palsy population. 2Oeffinger D et al 2008; GMFM-E = Gross Motor Function Measure Part E; 2MWT = 2-minute walk test; GMFCS = Gross Motor Function Classification System ; LS = least squares",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ff104be-ef4a-473b-87f9-f9b3827943e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.6,
        "y": 0.55
      },
      "kind": "table",
      "text": "LS Mean Difference and P-values for 2MWT",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1334090f-d8cc-4fd7-b547-178fd130944b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.1,
        "y": 0.55
      },
      "kind": "table",
      "text": "LS Mean Difference and P-values for GMFM-E",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c4d2078-a62f-427e-b64f-3a5b637d1590",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "PEACE Phase 3 Trial: Mobility Assessed by GMFM-E and 2MWT",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2db83de-9234-4d77-8f07-0117fa035ecd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "4114b6df-d0d5-47ec-bd8a-a18d8b41ce51",
      "evidence": "The document presents positive results from the Phase 3 clinical trial",
      "position": 1,
      "objective": "Show the potential of Pegzilarginase to improve patient outcomes",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}